ASO-mediated UBE3A-AS knockdown to de-repress paternal UBE3A: therapeutic rationale for c.67C>T (p.Arg23Ter)

Antisense oligonucleotide (ASO) targeting the UBE3A antisense transcript (UBE3A-AS) represents the most mechanistically compelling RNA therapy strategy for Angelman syndrome, including early-truncating variants like c.67C>T (p.Arg23Ter). By degrading UBE3A-AS, these ASOs de-repress the epigenetically silenced but structurally intact paternal UBE3A allele in neurons, bypassing the defective maternal copy entirely. Multiple clinical programs (GTX-102/Ultragenyx, ION582/Ionis, RO7248824/Roche) are in Phase 1/2 trials.

UBE3A is imprinted: only the maternal allele is expressed in neurons, while the paternal allele is silenced by the long non-coding UBE3A-AS transcript. In Angelman syndrome patients with maternal UBE3A loss-of-function, the paternal copy remains structurally intact but transcriptionally silenced. ASO-mediated knockdown of UBE3A-AS in mouse models (Ube3a^m-/p+) restored paternal Ube3a expression to approximately 40-90% of wild-type levels and rescued behavioral and electrophysiological phenotypes (Meng et al., Nature 2015; PMID:25533962). GTX-102 (GeneTx/Ultragenyx) entered clinical trials (NCT04259281) and showed preliminary evidence of UBE3A protein restoration in CSF biomarker studies, though the Phase 1/2 trial encountered dose-limiting lower extremity weakness at higher doses requiring protocol amendment. ION582 (Ionis) and RO7248824 (Roche) represent next-generation ASO programs with potentially improved therapeutic indices. For the c.67C>T variant specifically, the p.Arg23Ter nonsense mutation truncates maternal UBE3A at residue 23, abolishing all E3 ligase activity and nuclear localization — the paternal allele encodes wild-type UBE3A and is thus the ideal rescue target.

ASO therapy requires repeated intrathecal administration, imposing procedural burden on pediatric patients. The therapeutic window may be narrow: preclinical data suggest greater benefit with earlier intervention, and neuronal circuits already mis-wired may not fully recover. GTX-102 dose-limiting toxicity (lower extremity weakness) at higher doses raises safety concerns that newer ASOs must address. Long-term expression durability after each dose and optimal re-dosing intervals remain under investigation. This approach does not correct the maternal allele — it relies entirely on sufficient de-repression of the paternal copy, and the degree of paternal UBE3A restoration achievable in human neurons in vivo remains to be quantified. The c.67C>T variant has not been specifically studied in ASO trial cohorts.